The gap between who has the patients and who gets the trial.
Why Fairmont Clinical exists, and what we believe about which practices should have access to clinical research.
Eight years of watching the same pattern repeat.
Dr. Adanna Osei spent eight years as a practicing internist in a community-based practice outside Durham before founding Fairmont Clinical. Again and again, she watched pharmaceutical sponsors and CROs select large academic medical centers for trials in conditions she treated every week — hypertension, diabetes, cardiometabolic disease — not because the academic centers had better patients for the study, but because they already had the regulatory infrastructure, dedicated coordinators, and IRB relationships in place. Her own patient population was, in many cases, exactly who the study needed. Her practice simply had nowhere to start.
Building the missing infrastructure, rather than waiting for it.
She founded Fairmont Clinical to be the infrastructure independent practices don't have time to build themselves — regulatory start-up, dedicated research coordinators, patient recruitment systems, and data management — so that a community practice with the right patient population can actually compete for trial placements against institutions ten times its size.
The name comes from the street she grew up on, not from any claim about fairness in the abstract. She's aware of the coincidence and finds it useful rather than embarrassing.
Four things that haven't changed since 2013.
We say no to sites that aren't ready.
A feasibility assessment that always says yes isn't a feasibility assessment. We've turned down more site placements than we've accepted, because a failed trial hurts the practice's future prospects more than a missed opportunity does.
GCP compliance isn't optional paperwork.
Good Clinical Practice standards exist because trial data has to be trustworthy enough to change how medicine gets practiced. We treat every compliance requirement as load-bearing, not bureaucratic.
Recruitment integrity over recruitment speed.
We're measured on enrollment numbers like everyone else in this industry, but never at the cost of enrolling a patient who doesn't actually meet the protocol's criteria.
The physician stays the physician.
We provide the infrastructure. The site's principal investigator makes the clinical calls. We've walked away from sponsor relationships that tried to blur that line.
Meet the people running this day to day: Our Team, or see exactly what a trial looks like at a site on the Trial Lifecycle page.